Page 7 - MagSI Magazin Nr. 85_2021

www.awmf.org/uploads/tx_szleitlini- JCO.2015.61.2887 analyses from the VELOUR trial. Eur J
en/021-007OLl_S3_Kolorektales-Karzi- 13. Modest DP, Pant S, Sartore-Bianchi A. Cancer. 2014;50(2):320-331.
nom-KRK_2019-01.pdf Treatment sequencing in metastatic doi:10.1016/j.ejca.2013.09.013
5. Bahadoer RR, Dijkstra EA, van Etten B, colorectal cancer. Eur J Cancer. 22. Tabernero J, Yoshino T, Cohn AL, et al.
et al. Short-course radiotherapy follo- 2019;109:70-83. doi:10.1016/j.ej- Ramucirumab versus placebo in com-
wed by chemotherapy before total me- ca.2018.12.019 bination with second-line FOLFIRI in
sorectal excision (TME) versus preope- 14. Sorich MJ, Wiese MD, Rowland A, Ki- patients with metastatic colorectal
rative chemoradiotherapy, TME, and chenadasse G, McKinnon RA, Karape- carcinoma that progressed during or
optional adjuvant chemotherapy in lo- tis CS. Extended RAS mutations and after first-line therapy with bevacizu-
cally advanced rectal cancer (RAPIDO): anti-EGFR monoclonal antibody sur- mab, oxaliplatin, and a fluoropyrimi-
a randomised, open-label, phase 3 trial vival benefit in metastatic colorectal dine (RAISE): a randomised, double-
[published correction appears in Lan- cancer: a meta-analysis of randomi- blind, multicentre, phase 3 study [pu-
cet Oncol. 2021 Feb;22(2):e42]. Lancet zed, controlled trials. Ann Oncol. blished correction appears in Lancet
Oncol. 2021;22(1):29-42. doi:10.1016/ 2015;26(1):13-21. doi:10.1093/annon- Oncol. 2015 Jun;16(6):e262]. Lancet
S1470-2045(20)30555-6 c/mdu378 Oncol. 2015;16(5):499-508.
6. Le Voyer TE, Sigurdson ER, Hanlon AL, 15. Tejpar S, Stintzing S, Ciardiello F, et al. doi:10.1016/S1470-2045(15)70127-0
et al. Colon cancer survival is associa- Prognostic and Predictive Relevance 23. Kopetz S, Grothey A, Yaeger R, et al.
ted with increasing number of lymph of Primary Tumor Location in Patients Encorafenib, Binimetinib, and Cetuxi-
nodes analyzed: a secondary survey of With RAS Wild-Type Metastatic Colo- mab in BRAF V600E-Mutated Colorec-
intergroup trial INT-0089. J Clin Oncol. rectal Cancer: Retrospective Analyses tal Cancer. N Engl J Med.
2003;21(15):2912-2919. doi:10.1200/ of the CRYSTAL and FIRE-3 Trials [pu- 2019;381(17):1632-1643. doi:10.1056/
JCO.2003.05.062 blished correction appears in JAMA NEJMoa1908075
7. O'Connell MJ, Mailliard JA, Kahn MJ, et Oncol. 2017 Dec 1;3(12):1742]. JAMA 24. Mayer RJ, Van Cutsem E, Falcone A, et
al. Controlled trial of fluorouracil and Oncol. 2017;3(2):194-201. al. Randomized trial of TAS-102 for re-
low-dose leucovorin given for 6 months doi:10.1001/jamaoncol.2016.3797 fractory metastatic colorectal can-
as postoperative adjuvant therapy for 16. Stintzing S, Tejpar S, Gibbs P, Thiebach cer. N Engl J Med. 2015;372(20):1909-
colon cancer. J Clin Oncol. L, Lenz HJ. Understanding the role of 1919. doi:10.1056/NEJMoa1414325
1997;15(1):246-250. doi:10.1200/ primary tumour localisation in colo- 25. Grothey A, Van Cutsem E, Sobrero A,
JCO.1997.15.1.246 rectal cancer treatment and outco- et al. Regorafenib monotherapy for
8. Caplin S, Cerottini JP, Bosman FT, Con- mes. Eur J Cancer. 2017;84:69-80. previously treated metastatic colorec-
©FgSKW
standa MT, Givel JC. For patients with doi:10.1016/j.ejca.2017.07.016 tal cancer (CORRECT): an internatio-
Dukes' B (TNM Stage II) colorectal carci- 17. Tran B, Kopetz S, Tie J, et al. Impact of nal, multicentre, randomised, place-
noma, examination of six or fewer BRAF mutation and microsatellite in- bo-controlled, phase 3 trial. Lancet.
lymph nodes is related to poor progno- stability on the pattern of metastatic 2013;381(9863):303-312. doi:10.1016/
sis. Cancer. 1998;83(4):666-672. spread and prognosis in metastatic S0140-6736(12)61900-X
9. Sargent DJ, Goldberg RM, Jacobson SD, colorectal cancer. Cancer.
et al. A pooled analysis of adjuvant 2011;117(20):4623-4632. doi:10.1002/ Autoren: Dr. med. Annabel H. S. Alig,
chemotherapy for resected colon can- cncr.26086 Dr. med. Jobst C. von Einem, Prof. Dr.
cer in elderly patients. N Engl J Med. 18. Pietrantonio F, Petrelli F, Coinu A, et al. med. S. Stintzing
2001;345(15):1091-1097. doi:10.1056/ Predictive role of BRAF mutations in
NEJMoa010957 patients with advanced colorectal Korrespondierender Autor:
10. Alberts SR. Update on the optimal cancer receiving cetuximab and pani-
management of patients with colo- tumumab: a meta-analysis. Eur J Can-
rectal liver metastases. Crit Rev Oncol cer. 2015;51(5):587-594. doi:10.1016/
Hematol. 2012;84(1):59-70. j.ejca.2015.01.054
doi:10.1016/j.critrevonc.2012.02.007 19. André T, Shiu KK, Kim TW, et al. Pem-
11. Nordlinger B, Van Cutsem E, Gruen- brolizumab in Microsatellite-Instabili-
berger T, et al. Combination of surgery ty-High Advanced Colorectal Can-
and chemotherapy and the role of tar- cer. N Engl J Med. 2020;383(23):2207-
geted agents in the treatment of pati- 2218. doi:10.1056/NEJMoa2017699
ents with colorectal liver metastases: 20. Van Cutsem E, Cervantes A, Adam R,
recommendations from an expert pa- et al. ESMO consensus guidelines for Dr. med. Annabel Alig
nel. Ann Oncol. 2009;20(6):985-992. the management of patients with me- Assistenzärztin
12. Modest DP, Stintzing S, von Weikers- tastatic colorectal cancer. Ann Oncol. Charité - Universitätsmedizin Berlin
thal LF, et al. Impact of Subsequent 2016;27(8):1386-1422. doi:10.1093/ Medizinische Klinik mit Schwerpunkt
Therapies on Outcome of the FIRE- annonc/mdw235 Hämatologie, Onkologie und Tumor-
3/AIO KRK0306 Trial: First-Line Thera- 21. Tabernero J, Van Cutsem E, Lakomý R, immunologie (CCM)
py With FOLFIRI Plus Cetuximab or Be- et al. Aflibercept versus placebo in Charitéplatz 1, 10117 Berlin
vacizumab in Patients With KRAS combination with fluorouracil, leuco- Tel.: 030-450-613 258
Wild-Type Tumors in Metastatic Colo- vorin and irinotecan in the treatment Fax.: 030-450-7513337
rectal Cancer. J Clin Oncol. of previously treated metastatic colo- E-Mail: annabel.alig@charite.de
2015;33(32):3718-3726. doi:10.1200/ rectal cancer: prespecified subgroup www.tumor-online.de

Das Thema Nr. 85 · 04/2021 7